Stoke Therapeutics (NASDAQ:STOK) Rating Reiterated by Needham & Company LLC

Stoke Therapeutics (NASDAQ:STOK - Get Free Report)'s stock had its "buy" rating restated by research analysts at Needham & Company LLC in a report issued on Thursday, Benzinga reports. They currently have a $22.00 price objective on the stock. Needham & Company LLC's price target indicates a potential upside of 62.96% from the company's current price.

Several other equities research analysts also recently weighed in on the company. JPMorgan Chase & Co. raised their price target on Stoke Therapeutics from $6.00 to $13.00 and gave the stock a "neutral" rating in a report on Tuesday, March 26th. HC Wainwright reissued a "buy" rating and issued a $35.00 price target on shares of Stoke Therapeutics in a report on Tuesday, March 26th. TD Cowen raised Stoke Therapeutics from a "market perform" rating to an "outperform" rating in a report on Tuesday, March 26th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Stoke Therapeutics in a report on Thursday, April 4th. Finally, Canaccord Genuity Group lifted their target price on Stoke Therapeutics from $18.00 to $21.00 and gave the stock a "buy" rating in a report on Tuesday, March 26th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, Stoke Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $19.63.

Stoke Therapeutics Stock Performance

STOK stock traded up $0.74 during trading on Thursday, reaching $13.50. 527,925 shares of the company traded hands, compared to its average volume of 967,668. Stoke Therapeutics has a 12 month low of $3.35 and a 12 month high of $16.40. The business has a 50 day simple moving average of $7.68 and a 200 day simple moving average of $5.59. The company has a market capitalization of $625.10 million, a price-to-earnings ratio of -5.38 and a beta of 0.77.

Insider Activity

In related news, insider Barry Ticho sold 10,000 shares of the company's stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $4.80, for a total value of $48,000.00. Following the completion of the sale, the insider now directly owns 6,981 shares of the company's stock, valued at approximately $33,508.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Stoke Therapeutics news, insider Barry Ticho sold 10,000 shares of the stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $4.80, for a total transaction of $48,000.00. Following the completion of the sale, the insider now directly owns 6,981 shares of the company's stock, valued at approximately $33,508.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel Jonathan Allan sold 5,126 shares of the stock in a transaction that occurred on Thursday, March 28th. The stock was sold at an average price of $13.20, for a total value of $67,663.20. Following the sale, the general counsel now directly owns 2,598 shares of the company's stock, valued at $34,293.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 32,741 shares of company stock worth $223,115. 12.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Stoke Therapeutics

Hedge funds have recently bought and sold shares of the company. Swiss National Bank increased its position in Stoke Therapeutics by 8.2% during the first quarter. Swiss National Bank now owns 30,500 shares of the company's stock worth $642,000 after buying an additional 2,300 shares in the last quarter. JPMorgan Chase & Co. increased its position in Stoke Therapeutics by 20.8% during the first quarter. JPMorgan Chase & Co. now owns 19,608 shares of the company's stock worth $412,000 after buying an additional 3,374 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Stoke Therapeutics by 1.4% during the first quarter. Bank of New York Mellon Corp now owns 62,698 shares of the company's stock worth $1,320,000 after purchasing an additional 837 shares during the last quarter. MetLife Investment Management LLC boosted its holdings in shares of Stoke Therapeutics by 58.5% during the first quarter. MetLife Investment Management LLC now owns 11,621 shares of the company's stock worth $245,000 after purchasing an additional 4,289 shares during the last quarter. Finally, Rhumbline Advisers boosted its holdings in shares of Stoke Therapeutics by 7.6% during the first quarter. Rhumbline Advisers now owns 19,345 shares of the company's stock worth $407,000 after purchasing an additional 1,362 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.